Takeda Pharmaceutical (TAK) Receivables: 2018-2025

  • Takeda Pharmaceutical's Receivables rose 3.95% to $5.4 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $11.8 billion, marking a year-over-year decrease of 18.82%. This contributed to the annual value of $5.4 billion for FY2025, which is 1.31% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Receivables stood at $5.4 billion for Q1 2025, which was up 3.95% from $5.2 billion recorded in Q1 2024.
  • Takeda Pharmaceutical's 5-year Receivables high stood at $8.2 billion for Q1 2021, and its period low was $503.8 million during Q1 2023.
  • Moreover, its 3-year median value for Receivables was $5.2 billion (2024), whereas its average is $3.7 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Receivables tumbled by 92.65% in 2022, and later soared by 937.50% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Receivables (Quarterly) stood at $8.2 billion in 2021, then crashed by 92.65% to $600.1 million in 2022, then declined by 16.04% to $503.8 million in 2023, then soared by 937.50% to $5.2 billion in 2024, then rose by 3.95% to $5.4 billion in 2025.
  • Its Receivables stands at $5.4 billion for Q1 2025, versus $5.2 billion for Q1 2024 and $503.8 million for Q1 2023.